SCHEMBL1481280

SCHEMBL1481280

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1ccc(-c2ccc(OCCCCC(=O)O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.44
ALB P02768 1/20 0.44
FFAR1 O14842 4/20 0.41
FFAR4 Q5NUL3 3/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
CYSLTR2 Q9NS75 2/20 0.40
CYSLTR1 Q9Y271 2/20 0.40
AGER Q15109 1/20 0.39
CNR1 P21554 3/20 0.39
CYP2C9 P11712 1/20 0.38
SCN5A Q14524 1/20 0.38
FABP4 P15090 2/20 0.38
LTB4R Q15722 2/20 0.37
DHODH Q02127 1/20 0.37
KCNA3 P22001 1/20 0.37
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481279 1.00 PPARA (0.44) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1481103 0.99 ALB (0.46) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1480920 0.99 ALB (0.46) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1480918 0.99 ALB (0.46) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1481100 0.99 ALB (0.46) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1481594 0.97 FFAR4 (0.44) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1481591 0.97 FFAR4 (0.44) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1480656 0.97 ALB (0.48) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1480653 0.97 ALB (0.48) PPARAALBFFAR1FFAR4PPARG
SCHEMBL1481709 0.95 AGER (0.42) PPARAALBFFAR1FFAR4CYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ PPARA 2236/4885ALB 1690/4885FFAR1 1810/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ PPARA 2236/4885ALB 1690/4885FFAR1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.